72 related articles for article (PubMed ID: 8647158)
1. Natural killer cell activation after interferon administration in patients with metastatic renal cell carcinoma: an ultrastructural and immunohistochemical study.
Toliou T; Stravoravdi P; Polyzonis M; Vakalikos J
Eur Urol; 1996; 29(2):252-6. PubMed ID: 8647158
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of intratumoral natural killer cells in gastric carcinoma.
Ishigami S; Natsugoe S; Tokuda K; Nakajo A; Che X; Iwashige H; Aridome K; Hokita S; Aikou T
Cancer; 2000 Feb; 88(3):577-83. PubMed ID: 10649250
[TBL] [Abstract][Full Text] [Related]
5. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic indication of interferons for renal cell carcinoma].
Harano M; Naito S
Nihon Rinsho; 2006 Feb; 64 Suppl 2():647-51. PubMed ID: 16523970
[No Abstract] [Full Text] [Related]
7. [Long-term immunological study on postoperative adjuvant treatment with interferon-gamma in patients with renal cell carcinoma who underwent nephrectomy].
Miura H; Arai H; Matsuoka A; Yazawa K; Satoh E; Nishimura K; Honda M; Fujioka H
Hinyokika Kiyo; 1999 Feb; 45(2):79-83. PubMed ID: 10212778
[TBL] [Abstract][Full Text] [Related]
8. Natural killer (NK) cell assay within bladder mucosa of patients bearing transitional cell carcinoma (TCC) after interferon (IFN) therapy: an immunohistochemical and ultrastructural study.
Natsis K; Toliou T; Stravoravdi P; Kirtsis P; Grekou A; Barich A; Konstantinidis E; Gigis P
Int J Clin Pharmacol Res; 1997; 17(1):31-6. PubMed ID: 9403351
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma.
Schleypen JS; Baur N; Kammerer R; Nelson PJ; Rohrmann K; Gröne EF; Hohenfellner M; Haferkamp A; Pohla H; Schendel DJ; Falk CS; Noessner E
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):718-25. PubMed ID: 16467081
[TBL] [Abstract][Full Text] [Related]
10. Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis.
Wittnebel S; Da Rocha S; Giron-Michel J; Jalil A; Opolon P; Escudier B; Validire P; Khawam K; Chouaib S; Azzarone B; Caignard A
Cancer Res; 2007 Jun; 67(12):5594-9. PubMed ID: 17575122
[TBL] [Abstract][Full Text] [Related]
11. [Activity of natural killer (NK) cells and their stimulation in patients with hypernephroma].
Hofmann R; Lehmer A; Reidel G
Helv Chir Acta; 1984 Oct; 51(3-4):411-5. PubMed ID: 6209242
[No Abstract] [Full Text] [Related]
12. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
Rini BI; Weinberg V; Dunlap S; Elchinoff A; Yu N; Bok R; Simko J; Small EJ
Cancer; 2006 Feb; 106(3):566-75. PubMed ID: 16369983
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous administration of interferon alpha and gamma in patients with metastatic renal cell carcinoma.
Koga S; Nishikido M; Matsuya F; Kanetake H; Saito Y
Anticancer Res; 1999; 19(6C):5547-50. PubMed ID: 10697614
[TBL] [Abstract][Full Text] [Related]
14. [A case study of metastatic renal cell carcinoma in lungs showing complete response to continuous subcutaneous injection of interferon alpha and gamma].
Kawata N; Hirakata H; Igarashi T; Minei S; Hamano K; Kodama M; Yamamoto T; Takimoto Y
Hinyokika Kiyo; 1996 Jul; 42(7):509-12. PubMed ID: 8809559
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma.
Romero JM; Aptsiauri N; Vazquez F; Cozar JM; Canton J; Cabrera T; Tallada M; Garrido F; Ruiz-Cabello F
Tissue Antigens; 2006 Oct; 68(4):303-10. PubMed ID: 17026465
[TBL] [Abstract][Full Text] [Related]
16. [The impairments of natural killer cell activity and interferon response in advanced malignant disease].
Draca S
Srp Arh Celok Lek; 1994; 122(1-2):48-50. PubMed ID: 17972805
[TBL] [Abstract][Full Text] [Related]
17. Distribution of subtypes of metastatic renal-cell carcinoma: correlating findings of fine-needle aspiration biopsy and surgical pathology.
Mai KT; Alhalouly T; Lamba M; Yazdi HM; Stinson WA
Diagn Cytopathol; 2003 Feb; 28(2):66-70. PubMed ID: 12561022
[TBL] [Abstract][Full Text] [Related]
18. The effectors of killer activity induced by interferon-alpha and gamma in peripheral blood mononuclear cells.
Sakaguchi M; Kubota S; Nishikido M; Taniguchi K; Inuzuka S; Saito Y; Kanetake H; Koga S
Int J Mol Med; 2002 Sep; 10(3):317-20. PubMed ID: 12165807
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
